Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
2003 1
2005 1
2006 1
2007 1
2008 1
2010 3
2011 2
2012 1
2013 1
2015 1
2017 1
2020 1
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for bicalutamide al
Your search for bicalutamid-al retrieved no results
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Shipley WU, et al. N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529. N Engl J Med. 2017. PMID: 28146658 Free PMC article. Clinical Trial.
The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). ...Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of …
The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the …
A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.
Costa B, Vale N. Costa B, et al. Pharmaceutics. 2021 May 30;13(6):815. doi: 10.3390/pharmaceutics13060815. Pharmaceutics. 2021. PMID: 34070725 Free PMC article. Review.
Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon, Pembrolizumab or Bicalutamide, are already being tested in clinical trials for repurposing, alone or in combination. ...
Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon …
Profiling estrogen, progesterone, and androgen receptors in colorectal cancer in relation to gender, menopausal status, clinical stage, and tumour sidedness.
Refaat B, Aslam A, Idris S, Almalki AH, Alkhaldi MY, Asiri HA, Almaimani RA, Mujalli A, Minshawi F, Alamri SA, AlHussain MI, Baltow BA, Alqasmi MH, Basfar GT, Alosaimi OM, Muhayya IA. Refaat B, et al. Front Endocrinol (Lausanne). 2023 May 3;14:1187259. doi: 10.3389/fendo.2023.1187259. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37206439 Free PMC article.
Effects of 17beta-estradiol (E2), progesterone (P4), and testosterone alone or combined with the specific blockers of ERalpha (MPP dihydrochloride), ERbeta (PHTPP), PGR (mifepristone), and AR (bicalutamide) on cell cycle and apoptosis were also measured in the SW480 male a …
Effects of 17beta-estradiol (E2), progesterone (P4), and testosterone alone or combined with the specific blockers of ERalpha (MPP dihydroch …
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists' Group. See WA, et al. J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S7-16. doi: 10.1007/s00432-006-0132-6. J Cancer Res Clin Oncol. 2006. PMID: 16896884 Clinical Trial.
In addition, the clinical benefit of bicalutamide 150 mg in locally advanced patients, but not in those with localized disease, is consistent with the overall results from the EPC program (McLeod et al. BJU Int 97:247-254, 2006). Given the quality-of-life advantages …
In addition, the clinical benefit of bicalutamide 150 mg in locally advanced patients, but not in those with localized disease, is co …
The Biochemical Effects of Silver Nanoparticles and Spirulina Extract on Experimentally Induced Prostatic Cancer in Rats.
El-Magid ADA, AbdEl-Hamid OM, Younes MA. El-Magid ADA, et al. Biol Trace Elem Res. 2023 Apr;201(4):1935-1945. doi: 10.1007/s12011-022-03298-0. Epub 2022 Jun 11. Biol Trace Elem Res. 2023. PMID: 35689758 Free PMC article.
Spirulina revealed a significant reduction in the level of total and free prostatic specific antigen (PSA) to the same level as bicalutamide treatment, which was the same as the control group. Histopathological study revealed regression (75%) of the histological pattern of …
Spirulina revealed a significant reduction in the level of total and free prostatic specific antigen (PSA) to the same level as bicalutam …
[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer].
Kotake T, Usami M, Isaka S, Shimazaki J, Oishi K, Yoshida O, Ozono S, Okajima E, Kanetake H, Saitoh Y, Tsukagoshi S, Akaza H, Koiso K, Kameyama S, Honma Y, Aso Y, Nakano E, Okuyama A, Naito S, Kumazawa J, Niitani H, Taguchi T. Kotake T, et al. Hinyokika Kiyo. 1996 Feb;42(2):143-53. Hinyokika Kiyo. 1996. PMID: 8712091 Free article. Clinical Trial. Japanese.
A phase I study (open trial) of bicalutamide (Casodex), a non-steroidal antiandrogen, was conducted on 16 patients with prostatic cancer (stage C to D). The patients were given 10, 30, 50, 80 or 100 mg of bicalutamide orally daily for 12 weeks. Adverse reactions wer …
A phase I study (open trial) of bicalutamide (Casodex), a non-steroidal antiandrogen, was conducted on 16 patients with prostatic can …
Growing Up Fast: Managing Autism Spectrum Disorder and Precocious Puberty.
Finkle A, Zavertnik S, Myers S, Cormier D, Heithaus J, Augustyn M. Finkle A, et al. J Dev Behav Pediatr. 2020 Dec;41(9):740-742. doi: 10.1097/DBP.0000000000000865. J Dev Behav Pediatr. 2020. PMID: 33214411
FMPP, also referred to as testotoxicosis, was attributed as the cause of John's peripheral precocious puberty.By the age of 4, John's height Z-score was +3.1, his genitalia larger, and his bone age 10 years (+10.3 S.D.). His parents elected to start off-label therapy with bica …
FMPP, also referred to as testotoxicosis, was attributed as the cause of John's peripheral precocious puberty.By the age of 4, John's height …
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S. Yanagisawa T, et al. World J Urol. 2023 Aug;41(8):2051-2062. doi: 10.1007/s00345-022-04030-2. Epub 2022 May 21. World J Urol. 2023. PMID: 35596809 Free PMC article.
METHODS: The records of 382 patients who harbored high-volume mHSPC, based on the CHAARTED criteria, and had received ADT with either docetaxel (n = 92) or NSAA (bicalutamide) (n = 290) were retrospectively analyzed. The cohorts were matched by one-to-one propensity scores …
METHODS: The records of 382 patients who harbored high-volume mHSPC, based on the CHAARTED criteria, and had received ADT with either doceta …
Words of wisdom. Re: Does oral antiandrogen use before leuteinizing hormone-releasing therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Oh WK, Landrum MB, Lamont EB, et al. Urology 2010;75:642-7.
Pavone-Macaluso M. Pavone-Macaluso M. Eur Urol. 2010 Aug;58(2):314-5. doi: 10.1016/j.eururo.2010.05.018. Eur Urol. 2010. PMID: 20845534
Oh et al report their experience with 1566 metastatic prostate cancer patients treated with luteinising hormone-releasing hormone (LHRH) agonists in the area of Boston, Massachusetts, USA. Of these patients, 79.5% were given antiandrogens (bicalutamide, flutamide, o …
Oh et al report their experience with 1566 metastatic prostate cancer patients treated with luteinising hormone-releasing hormone (LH …
21 results